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INTRODUCTION
India currently leads the world in number of people with 
diabetes. The Diabetes Atlas published by the International 
Diabetes Federation shows there are currently over 40 
million diabetic patients in India. These numbers are 
predicted to increase to 69 million by 20251. Furthermore, 
India occupies the second position with respect to the 
number of patients with impaired glucose tolerance (IGT)2. 
By the year 2025, India shall have the maximum number of 
diabetics in the world making it, the “Diabetic capital of the 
world”2. The prevalence of the disease in adult is 2.4% in 
rural and 4.0 - 11.6% in urban dwellers2-4.
The increased prevalence is attributed to the aging 
population structure, urbanization, the obesity epidemic, 
and physical inactivity. These changes are more obvious in 
urban residents who consume 32% of energy from fat as 
compared with 17% in rural residents5.
Psychological stress, depression, and short sleeping hours, 
which have become increasingly common in developing 
countries undergoing rapid economic developments, have 
been associated with higher risk of the metabolic syndrome 
and diabetes in Asian population6.
Diabetes mellitus refers to a group of common metabolic 
disorders that shares a phenotype of   hyperglycemia. Once 
regarded as a single disease entity diabetes is now seen as a 
heterogenous group of disease characterized by a state of 
chronic hyperglycemia resulting from a diversity of 
etiologies, environmental and genetic acting   jointly1. 
While Type I diabetes is an autoimmune disease which 
results into pancreatic beta cell death and resultant lack of 
Insulin production, Type II diabetes is scientifically most 
challenging disease, which is characterized by elevated
insulin resistance and glucose intolerance. Type II diabetes 
can occur as a result of dysfunction in glucose, lipid and 
energy homeostasis in organs/organ systems including 
liver, adipose, muscle, gastrointestinal tract. Elevated levels 
of serum glucose and free fatty acids occurring due to 
imbalances in lipid and carbohydrate metabolism then leads 
to endoplasmic reticular stress in pancreatic beta cells, 
leading ultimately to pancreatic beta cell death (terminal 
diabetes).
Despite the great understanding of pathophysiology and 
meticulous efforts towards management of diabetes, the 
disease and related complications are still increasing due to 
multiple defects. The aim of the management of diabetes is 
to maintain euglycemia and prevention of various micro 
and macro-vascular complications of diabetes mellitus.
Various modalities available for the management of
diabetes are :-
 Diet restriction
 Exercise 
 Drugs:- these includes oral hypoglycemic drugs and 
insulin.
Among oral hypoglycemic drugs insulin secretagogue (like 
sulfonylurea,      meglitinide derivative),  insulin sensitizer  
thiazolidinediones        ( like pioglitazone, rosiglitazone) 
and Biguanides ( like Metformin) and α Glucosidase 
inhibitors (Acarbose, Miglitol). Also there are some 
recently developed drugs like amylin agonist (Pramlintide), 
analog of glucagon like peptide-1(GLP-1 analog eg. 
Exenatide and Liraglutide), and Inhibitor of Dipeptidyl 
peptidase-4 (DPP-4 inhibitor eg. Sitagliptin).
Inspite of all these commomly used drugs,the research is 
still going on for an ideal antidiabetic with minimal side 
effects and better compliance . In this line other 
mechanisms of diabetes pathophysiology is being searched 
exhaustively. One such mechanism is “role of 
hypothalamus and neurohormonal circuitary in glycemic
control ” which incorporates the cross talk between blood 
born factors and neurons. This theory emphasizes that 
altered circadian neuroendocrine rhythm (Dopamine, 5-HT 
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and Norepinephrine) in the hypothalamus is seen in 
diabetes mellitus7,8. Studies shows that reduce
dopaminergic tone has a pivotal role in the development of 
diabetes mellitus. So, dopaminergic agonists may help in 
resetting the altered dopaminergic tone and thus it can be of 
help in controlling diabetes mellitus.
BROMOCRIPTINE
Bromocriptine mesulate quick release formulation has been 
approved by FDA for the treatment of diabetes mellitus in 
adultas an adjunct to diet and exercise to improve glycemic 
control.
                                  Ergocriptin                                                           
Mechanism of action: Bromocriptine is a sympatholytic 
D2 dopamine agonist. This acts as a centrally acting 
antidiabetic agent and reduces plasma glucose, triglyceride 
and free fatty acid levels, and also has some 
cardioprotective action. A quick release formulation of 
Bromocriptine, administered within two hours of 
awakening, is believed to augment low hypothalamic 
dopamine level and inhibit excessive sympathetic tone 
within central nervous system, resulting in decrease in 
plasma glucose level7,9.
Background: The idea of using bromocriptine for the 
treatment of type 2 diabetes came while studying the 
metabolism of migrating birds. It was noted that their 
hypothalamus have the ability to develop seasonal 
resistance by controlling their metabolism
differential processing of fuel during different part of the 
day7. Also, when food availability is low during the harsh 
winter month, birds develop  an insulin resist
intolerant state so that thare is increased bas
activity and spared glucose utilization in peripheral tissues 
and increase hepatic glucose output that helps in
functioning of CNS. This CNS mediated increase 
glucose output protects the brain against glucopenia
Metabolically, the excess insulin production
resistance to insulin, and elevated cholesterol levels helps 
them in storing the excess energy they are consuming that 
is necessary for the expected hibernation or migration. 
Thus the final benefit is improved survival in times of 
seasonal famine or when food availability is low.
Role of hypothalamus in glycemic control and insulin
sensitivity
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Chemistry: Bromocriptine,( ie. 2-bromoergocriptine, is a
semisynthetic derivative of a 
natural ergot alkaloid, ergocriptin (a derivative of
acid), which is synthesized by bromination of ergocriptin 
using N-bromosuccinimide.
The structural formula of bromocriptine is shown in figure. 
Bromocriptine mesylate is a white or slightly colored, fine 
crystalline powder with a molecular fo
N 5 O 5 CH 4 SO 3 and a molecular weight of 750.72.
                                Bromocriptine
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The hypothalamus (from Greek Hypo
Thalamus = room, chamber) is a portion of the
links the nervous system to the endocrine system
the pituitary gland (hypophysis).
The hypothalamus is located below the
above the brain stem. It forms the
the diencephalon. All vertebrate brains contain a 
hypothalamus.The hypothalamus is responsible for 
certain metabolic processes and other activ
the autonomic nervous system. It synthesizes and secretes 
certain neurohormones, often called hypothalamic
hormones, and these in turn stimulate or inhibit the 
secretion of pituitary hormones. The hypothalamus 
controls body temperature, hunger, thirst
and circadian cycles7.
The hypothalamus receives information about changes in 
the internal and external environment from
like the neurons of peripheral organs, from
and from the blood (fatty acids, glucose, and hormones).
brings about adjustments to these changes through 
integration and assessment of the peripheral information
that include not only somatic movement but also changes in 
the rate at which hormones are secreted.
For example circadian rhythms are controlled by 
subchiasmatic nuclei of hypothalamus by receiving the 
light information from the eyes
hypothalamic nuclei controls the food intake
endogenous hepatic gluconeogenesis, and muscle 
glycogensis are done by receiving the information of 
glucose, insulin and fatty acids in the blood.
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                                               Role of Hypothalamus in metabolism
Ventromedial hypothalamus acts as a glucose sensor. It has 
multiple connections with other hypothalamic nuclei and 
plays a pivotal role in modulating autonomic nervous 
system function, hormonal secretion, peripheral glucose, 
lipid metabolism, and feeding behavior. Hypothalamic 
subchiasmatic nucleus oscillates with respect to metabolic 
signals it receives such as at the time of adequate food 
intake, it senses the fatty acid and insulin and so it inhibits 
endogenous glucose production from liver, stimulate 
glycogen synthesis in muscle and reduces food intake.
                
Response of Hypothalamus to increased fatty acid and insulin in blood
Role of hypothalamus in diabetes
Altered circadian neuroendocrine rhythm affects the 
glycemic control of the body. Reduction in hypothalamic 
dopaminergic activity and increased noradrenergic tone 
play a pivotal role in the development of body fat stores 
and insulin sensitivity. Reduced dopaminergic tone in the 
hypothalamus results in excessive glucose production in the 
liver, and increased peripheral insulin resistance11-13. 
Hypothalamus doesnot respnds to the rise in glucose and 
lipids after meals and so it doesnot stimulate splanchnic 
glucose disposal thus the result is hyperglycemia not 
responding to rise in insulin ie diabetes mellitus.
Proposed mechanism of action of bromocriptine to improve glucose homeostasis and insulin sensitivity
Bromocriptine is a sympatholytic dopamine D2 receptor 
agonist. It is unique in that it doesnot have a specific 
receptor that mediates its action on glucose and lipid 
metabolism14-17. Its effects are mediated via resetting of 
dopaminergic and sympathetic tone within the CNS.
Systemic and intracerebral administration of bromocriptine
in insulin-resistant animals leads to a decrease in elevated 
VMH noradrenergic and serotonergic levels with a resultant 
decline in hepatic glucose production / gluconeogenesis, 
reduced   adipose  tissue lipolysis, and improved insulin 
sensitivity11-17.Systemic bromocriptine also inhibits VMH 
responsiveness to norepinephrine, and, conversely, 
norepinephrine infusion into the VMH antagonizes the 
beneficial effect of bromocriptine on glucose tolerance and 
insulin sensitivity. Consistent with these observations in 
animals, systemic bromocriptine administration improves 
glycemic control and dyslipidemia without change in body 
weight in type 2 diabetic and obese nondiabetic humans. 
HYPOTHALAMIC 
INTEGRATION OF 
PERIPHERAL 
INFORMATION
INPUTS FROM 
BLOOD (GLUCOSE, 
FATTY ACID, 
INSULIN)
INPUTS FROM 
PERIPHERAL  
ORGANS (EYE, 
MUSCLES)
METABOLIC CONTROL
↑FATTY 
ACID AND 
INSULIN IN 
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AND 
GLYCOGENOLYSIS
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GLYCOGENESIS
↓FOOD 
INTAKE
↓TRIGLYCERIDE    
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Early morning bromocriptine increases the morning 
hypothalamic dopamine level, that results in decreased 
noradrenergic tone, decreased hepatic glucose production, 
decreased lipolysis and lipogenesis. These factors improves 
the glucose tolerance, insulin sensitivity and decrease 
plasma free fatty acid, triglyceride thus improves glycemic 
control in diabetic patients7,11-13.
This finding suggests that systemic Bromocriptine alters 
the monoamine neurotransmitter level within hypothalamic 
circadian centers and by doing so, they exert significant 
effects on glucose and lipid metabolism9.
                                                                                                                                                                                                                
                  
Effects of early morning bromocriptine
Dose 
The recommended dose of bromocriptine is 1.6 mg to 4.8 
mg, taken  within two hours after waking in the morning18. 
It should be taken with food to potentially reduce the 
gastrointestinal side effects such as nausea20-22. Adverse 
events reported during various clinical trials of 
bromocriptine included fatigue, nausea, vomiting, 
dizziness, and headache. These events were more likely to 
occur during initiation of the treatment and later they were 
subsided after proper titration of drug. In a 52-week safety 
clinical trial, bromocritpine mesylate was used at a dosage 
of 0.8-4.8 mg/day; incidence of nausea was 32.2 % and that 
of fatigue, vomiting, headache, and dizziness were 13.9, 
8.1, 11.4, and 14.8%, respectively18. No dyskinesia was 
observed during the period of clinical trial18.
Pharmacokinetics
Following ingestion, bromocriptine mesylate tablets are 
dissolved rapidly and get absorbed within 30 min. When 
ingested in an empty stomach, the maximum plasma 
concentration is reached within 60 min18. Food delays the 
absorption and peak plasma levels are reached within 120 
min in the fed state. There is extensive hepatic first-pass 
metabolism by the cytochrome P450 system, specifically 
CYP3A4. Only 5–10% of the ingested dose reaches the 
systemic circulation.  Ninety-eight percent of ingested 
bromocriptine is excreted via the biliary route with an 
elimination half-life of about six hours18.
Non diabetic uses of bromocriptine
Bromocriptine is used for various fields of medicine like it 
is used by endocrinologists for the management of pituitary 
adenomas and hyperprolactinemia, by gynecologists for 
suppression of lactation, by neurologists in Parkinson's 
disease and restless legs syndrome, and by cardiologists as 
a treatment for peripartum cardiomyopathy. In pychiatry it 
is used for anhedonia in depressed patients19.
Conclusion
Diabetes mellitus is a chronic metabolic syndrome . It 
involves multiple organ of the body and leads to various 
complications. At present a large number of oral 
hypoglycemic agents and insulin are available for the 
treatment of type 2 diabetes. There are some recently 
included drugs like amylin agonist (Pramlintide), analog of 
glucagon like peptide-1(GLP-1 analog eg. Exenatide and 
Liraglutide), and  inhibitor of dipeptidyl peptidase-4 (DPP-
4 inhibitor eg. Sitagliptin).But still there is a need for the 
development of an antidiabetic agent with minimal side 
effect and good compliance with different mechanism of 
action from existing drugs. The traditionally used oral 
agents are associated with increased risk of adverse events
like hypoglycemia, weight gain. lactic acidosis. Also during 
treatment for long time, their effectiveness decreases due to 
progressive beta cell failure and later they fail to achieve 
target glycemic control. So they are used as a combination 
therapy. 
Bromocriptine, used as a novel antidiabetic agents, is a 
dopamine receptor (D 2) agonist, commonly  used for 
hyperprolactinemia and parkinsonism. Bromocriptine is
recently approved for the treatment of type 2 diabetes in 
addition to diet and exercise. It helps to achieve proper
glycemic control. A number of studies carried out have 
shown that early morning bromocriptine reduces FBS, 
PPBS and HbA1c level significantly. A study done by
Scranton et al. observed the control of hyperglycemia in 
study subjects with the administration of quick release
formulation of bromocriptine. This was also associated 
with 42% reduction in the episodes of myocardial 
infarction, stroke, coronary revascularization, and 
hospitalization in patients suffering from angina or 
congestive heart failure and a 55% reduction in the 
episodes of myocardial infarction, stroke, or death.
Bromocriptine had shown favourable effects in patients of 
type 2 diabetes as well as in dyslipidemia. Kamath et al. 
(1997)15 reported a significant reduction in hyperglycemia 
and dyslipidemia in obese nondiabetic hyperinsulinemic 
women. Cincotta et al. (1999)16 observed significant 
improvement of blood sugar and hyperlipidemia with quick 
release bromocriptine, administered daily for 6 months.
Pijl et al. (2000)14 observed significant reduction in levels 
EARLY MORNING 
BROMOCRIPTINE 
↑  HYPOTHALAMIC    
DOPAMINE LEVEL
↓NORADRENERGIC TONE
↓HEPATIC GLUCOSE PRODUCTION
↓LIPOLYSIS
↓PLASMA FREE FATTY ACID
↑ GLUCOSE  TOLERANCE
↓BLOOD GLUCOSE
↑INSULIN SENSITIVITY
↓PLASMA FREE FATTY ACID  
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of both fasting and postprandial (pp) blood glucose level. 
Aminorroaya et al., (2004)17 administered bromocriptine 
2.5 mg daily for 3 months and observed a significant 
decrease in fasting blood sugar and HbA1c level.
Therefore all these studies demonstrated one thing in 
common that quick release bromocriptine may prove to be 
a landmark in the treatment of non-insulin dependent 
diabetes mellitus. It will be beneficial in obese patients as it 
takes care of both dyslipidemia as well as hyperglycemia.
Thus this drug can be used for its favourable effect to 
control all the components of the metabolic syndrome.
Further, studies are needed to prove its beneficial effect in 
reduction of body weight in obese diabetics. That will 
ensure it a preferred agent in obese diabetic patients not 
responding to conventional oral antidiabetic drugs. Novel 
mechanism of action, single daily dose, favourable change 
in lipid profile and lower incidence of cardiovascular 
events are the points that favors the use of bromocriptine in 
treatment of type 2 diabetes.
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